Ownership & Insider Lab

Look up a company to review current SEC-traceable insider positions, exact reporting-owner relationships across other published companies, a dated chronology of the published ownership evidence, and recent supported insider transactions where transaction history is separately available.
Coverage follows the existing reviewed company dataset and fails closed when a ticker is not currently supported.

Krystal Biotech, Inc. (KRYS)

Nasdaq · SEC CIK 0001711279

$933.96MCovered current disclosed holdings
3Covered reporting owners
3Covered direct positions
3Source ownership filings

This is the supported SEC-traceable subset, not total insider ownership or personal wealth. Values reflect the current disclosed positions Grizzly Bulls can resolve and value. Latest source filing: Sep 4, 2026 · values through Sep 25, 2026.

Covered reporting owners

Filter the reporting-owner snapshot by holder, role, or security. Position values are shown only where the current reviewed data supports them.

3 shown
HolderRolePositionCurrent valueLatest filing
Krish S. KrishnanResearch disclosed relationshipsPresident and CEO · Director · 10% owner1,347,543 sharesCommon Stock$466.18MSep 4, 2026
Suma KrishnanResearch disclosed relationshipsPresident, R&D · Director · 10% owner1,302,145 sharesCommon Stock$450.48MSep 4, 2026
Dino A. RossiResearch disclosed relationshipsDirector50,000 sharesCommon Stock$17.3MAug 14, 2026

Reporting-owner research graph

These relationships are joined only when the same single SEC reporting-owner CIK appears unambiguously across the publication-authorized company ownership universe. Name similarity is never used to create a relationship.

This graph is bounded to the company ownership relationships currently published by Grizzly Bulls. It is not a complete employment, board, ownership, portfolio, or wealth history, and a missing relationship does not establish that none exists.

SEC transaction evidence ledger

Each row preserves the reviewed SEC transaction evidence, including the effective-date basis, amendment state, reported post-transaction position when present, and a separately published current covered owner/security position when one can be matched uniquely. Reported price is shown when present. The lab does not calculate gross proceeds, reconstruct balances between filings, or treat historical transactions as current wealth.

12 shown
Effective dateHolderActionSecurityUnitsReported priceReported position after transactionCurrent covered positionFiling
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock399 shares$366.5561,302,145 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock826 shares$365.41391,302,544 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock1,329 shares$364.47711,303,370 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock565 shares$363.34041,304,699 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock1,992 shares$362.65271,305,264 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock1,242 shares$361.611,307,256 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock2,320 shares$360.4661,308,498 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock3,392 shares$359.38621,310,818 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock3,180 shares$358.42031,314,210 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock3,962 shares$357.57421,317,390 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock3,267 shares$356.36791,321,352 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026
Sep 4, 2026Transaction dateSuma KrishnanResearch disclosed relationshipsSaleSEC code SCommon Stock2,006 shares$355.57191,324,619 shares1,302,145 sharesOwner coverage latest filing Sep 4, 20264Filed Sep 4, 2026

A reported post-transaction position is the balance stated in that historical transaction filing. A current covered position is a separate latest owner/security observation and may reflect later filings or activity. They are shown side by side as evidence points, not as a reconstructed continuous ledger.

Published 12 of 35 source candidates under the current reviewed security-resolution rules.

Covered securities

SecurityInstrument familyCovered positionsCovered value
Common Stockordinary-share3$933.96M

Coverage and interpretation

Current holdings: direct positions that the reviewed ownership data can trace to an exact reporting owner, legal security, and current-basis quantity.

Current value: the existing published company-position valuation. This lab does not recalculate security values or infer missing positions.

Transaction evidence: historical flow observations with filing provenance. Reported post-transaction balances and current covered positions are separate evidence points; the lab does not interpolate ownership between them.

Reporting-owner graph: exact reporting-owner CIK relationships across the published company universe. It does not merge people by name or create a complete personal history.

Not included here: a claim of total insider ownership, total personal wealth, institutional 13F ownership, a transaction-value estimate, an insider sentiment score, or an investment recommendation.

Published ownership evidence chronology

This sequence orders only the ownership evidence already published by Grizzly Bulls for the exact reporting-owner relationships above. Transaction rows are ordered by filing date while preserving the separate economic effective date and its basis. Current covered snapshots remain separate latest observations.

The chronology does not interpolate ownership between entries, infer missing activity, pair an amended filing with an assumed parent, infer amendment supersession, or treat a current covered snapshot as proof of continuous ownership.

Dino A. Rossi

SEC reporting-owner CIK 0001209059 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Aug 14, 2026Latest represented filing dateKrystal Biotech, Inc. (KRYS)NasdaqCurrent covered snapshotDirectorValuation observation Sep 25, 2026Common Stock: 50,000 sharesCurrent covered company value: $17.3MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 0 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Krish S. Krishnan

SEC reporting-owner CIK 0001298709 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Sep 4, 2026Latest represented filing dateKrystal Biotech, Inc. (KRYS)NasdaqCurrent covered snapshotPresident and CEO · Director · 10% ownerValuation observation Sep 25, 2026Common Stock: 1,347,543 sharesCurrent covered company value: $466.18MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 0 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Suma Krishnan

SEC reporting-owner CIK 0001298711 · 1 published relationship company

SEC owner filings
Evidence dateCompanyObservationSecurity / positionSource
Sep 4, 2026Latest represented filing dateKrystal Biotech, Inc. (KRYS)NasdaqCurrent covered snapshotPresident, R&D · Director · 10% ownerValuation observation Sep 25, 2026Common Stock: 1,302,145 sharesCurrent covered company value: $450.48MPublished current ownership snapshotForms represented: 4Owner filingsIssuer filings
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 2,006 shares · reported price 355.5719Common StockReported position after transaction: 1,324,619 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 1,329 shares · reported price 364.4771Common StockReported position after transaction: 1,303,370 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 826 shares · reported price 365.4139Common StockReported position after transaction: 1,302,544 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 399 shares · reported price 366.556Common StockReported position after transaction: 1,302,145 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,267 shares · reported price 356.3679Common StockReported position after transaction: 1,321,352 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,962 shares · reported price 357.5742Common StockReported position after transaction: 1,317,390 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,180 shares · reported price 358.4203Common StockReported position after transaction: 1,314,210 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 3,392 shares · reported price 359.3862Common StockReported position after transaction: 1,310,818 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 2,320 shares · reported price 360.466Common StockReported position after transaction: 1,308,498 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 1,242 shares · reported price 361.61Common StockReported position after transaction: 1,307,256 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 1,992 shares · reported price 362.6527Common StockReported position after transaction: 1,305,264 shares4 filing0001298711-26-000009
Sep 4, 2026Filed dateKrystal Biotech, Inc. (KRYS)NasdaqSaleSEC code SEffective Sep 4, 2026 · transaction dateReported units 565 shares · reported price 363.3404Common StockReported position after transaction: 1,304,699 shares4 filing0001298711-26-000009

Company-level recent transaction history is published for 1 of 1 relationship companies in this graph; 12 published transaction rows for this exact reporting-owner CIK appear in the chronology. 1 relationship company is at the current public transaction-row limit; that does not prove additional rows exist.

Continue this ownership research

These handoffs preserve the exact company identities already represented in the reporting-owner graph. My Stocks keeps a listed company in your existing research lists. Research Inbox is a separate company-change update workflow.

Saving a company to My Stocks never enables updates, and opening Research Inbox never subscribes you automatically. Each update remains an explicit company-level opt-in under the existing Research Inbox consent flow.

CompanyReporting-owner contextPublished evidenceContinue research
Krystal Biotech, Inc. (KRYS)Nasdaq · Current company15Published chronology observationsLatest represented evidence Sep 4, 2026

These are company-level continuation paths, not reporting-owner subscriptions. Saving or watching one company does not automatically save or watch the other companies connected to the same reporting owner, and it does not create an owner-level alert.